Kornimate/medical-research-clean huggingface dataset:
the effect of mindfulness-based relapse prevention on impulsive control circuit among methamphetamine dependents

Conditions: Methamphetamine-dependence

Summary: amphetamine-type stimulants (atss) have become the most important medical issue as well as the social problem. compared with traditional drugs, ats are highly neurotoxin and can induce cognitive deficit and psychotic symptoms. due to lack of efficient medical treatment, psychotherapy and behavioral interventions are the main treatment strategies so far. mindful-based relapse prevention (mbrp) which combined mindfulness with relapse prevention skills, as a novel intervention, has been widely used in prevent craving and relapse among addictions. while the current research of mbrp mechanism focus on emotion regulation circuit, and there was no study to explore the impulsive circuit, which is the important factor that induce the addiction and relapse. however, there was no report about the influence of mbrp on prefrontal-striatal circuits. based on the previous results, the proposed study will focus on evaluating the mechanism of mbrp on prefrontal-striatal circuits, neuropsychological tests and functional mri will be used to investigate the neurobiological mechanism of mbrp on prefrontal-striatal circuits and related impulsive behaviors.


Eligibility criteria:
inclusion criteria: * 18-45 years old, male or female, with 9 years of education or above, can cooperate with the completion of the questionnaire evaluation; * comply with dsm-v diagnostic criteria for amphetamine-based addiction; * the previous use of amphetamines for not less than 1 year (at least once a week); * vision and hearing are normal, or in the normal range after correction. no contraindications for magnetic resonance imaging; * agree to cooperate with the completion of follow-up evaluation; * the mindfulness attention awareness scale score is greater than 50 points. exclusion criteria: * severe cognitive dysfunction, such as history of head trauma, cerebrovascular disease, epilepsy, etc., drugs used to promote cognitive function in the last 6 months; intellectual impairment iq\<70; * there have been other abuse or dependence of psychoactive substances in the past 5 years (excluding nicotine); 100 healthy controls have been publicly collected by the public. exclude serious physical illness and mental damage. through * scid clinical interviews exclude family history of mental disorders and psychosis, no history of substance abuse (except nicotine).

Keywords: mindfulness-based relapse prevention methamphetamine prefrontal-striatal circuit impulsive mechanism
food insecurity reduction & strategy team

Conditions: Diabetes Mellitus, Type 2; Food Insecurity; Diabetes Mellitus, Type 1

Summary: this study seeks to address the multifaceted challenges posed by food disparities and their negative consequences on health outcomes, via a comprehensive community health intervention program. study objectives include: 1. to describe the social-demographic and clinical factors associated with food insecurity in the hospitalized diabetic population. 2. to design, implement and evaluate a nutrition program targeting the hospitalized diabetic population. the investigators will prospectively randomize the target population into either a nutrition program (intervention), or state-of-art standard of care (soc) in a 4:1 ratio. participants in the intervention group will be provided the following two resources in addition to soc: 1) enhanced access to nutritious food (twice daily meal delivery up to 90 days post-discharge) 2) education at discharge and continuing outreach to enhance knowledge for better diet and food options. 3. to enhance community engagement and develop a systematic implementation plan for long-term roll-out of the nutrition program.


Eligibility criteria:
inclusion criteria: * diagnosis of type 1 or type 2 diabetes mellitus * admitted to stanford healthcare inpatient unit * residence in california at time of enrollment * positive screening for food insecurity * on a healthcare plan covered by mom's meals. exclusion criteria: * plans to be discharged to a skilled nursing facility. * patients who prefer a language for which a short-form consent is not available. * no home address * pregnant participants. * no access to refrigerator.

Keywords: inpatient
the effect of epidural fentanyl on immune function

Conditions: Malignancy

Summary: background: for cancer to grow and metastasize, inflammatory and immunologic conditions in the host must be favorable. the perioperative period provides inflammatory and immunologic changes that may be pro-malignant. anesthetic medications, including the use of opioid medication, may contribute to these changes. hypothesis: the investigators hypothesize that perioperative immunologic changes in patients undergoing resection of hepatic colorectal cancer recurrence, as measured by natural killer cell function and cytokine levels, will undergo less alterations in those who receive only epidural bupivacaine, as compared to those who receive epidural bupivacaine and fentanyl. methods: in this double blind control trial patients with no extra-hepatic evidence of cancer, undergoing a planned curative resection of hepatic recurrence of colorectal cancer, will be randomized to receive an epidural with bupivacaine and fentanyl, or bupivacaine alone. no other perioperative opioid medication will be given, and post-operative analgesia will be supplemented with acetaminophen and gabapentin. blood samples and pain ratings using a verbal analogue scale will be obtained preoperatively, immediately and 6 hours postoperatively, and then daily until removal of the epidural catheter. samples will be analyzed for levels of interleukin 2, 6, 8, 10, 12, 16, 17,tnf-α, tgf α and β, mcp-1, crp, and nk cell activity. cytokines will be measured using a suspension bead array immunoassay kit, and nk activity will be measured using flow cytometry of isolated peripheral blood mononuclear cells exposed to the k562 cell line and treated with fluorescent antibodies to intracellular markers of activation. data will be compared between groups using t-tests, or mann-whitney tests as appropriate. to demonstrate a 50% smaller decrease of nk cell activity in the bupivacaine group as compared to the bupivacaine and fentanyl group the investigators will need to randomize a total of 30 patients.


Eligibility criteria:
inclusion criteria: we will consider for inclusion any adult patient undergoing a planned curative hepatic resection of a colorectal carcinoma liver recurrence. exclusion criteria: e 3. patients excluded any patient unable to communicate in english or french. any patient with evidence of extra-hepatic metastasis. any patient with contra-indications to epidural anesthesia, or any of the medications used in the study. any patient with evidence of coronary artery disease or congestive heart failure, either previously or currently. any patient with insulin treated diabetes. any patient with a bmi greater than 40. any patient who has received steroids in the past 2 months. any patient who has taken any pain medication the week before surgery. any pregnant or breast feeding patient. any patient with a chronic inflammatory disease, including but not limited to lupus, rheumatoid arthritis, and inflammatory bowel disease.

Keywords: opioid malignancy epidural
physical activity in rectal cancer survivors

Conditions: Rectal Cancer; Rectosigmoid Cancer

Summary: the goal of this clinical trial is to test a telehealth-based personalized physical activity intervention in adult patients diagnosed with stage i-iii rectal cancer. the main question it aims to answer are how to better understand the experiences of rectal cancer survivors who are coping with bowel dysfunction and how physical activity can improve their quality of life. participants will be asked to: 1. complete surveys to assess bowel function and quality of life 2. participate in 12 telehealth sessions (one session a week) to discuss and review bowel dysfunction 3. perform daily physical activity

the goal of this clinical trial is to administer and determine the feasibility of a personalized physical activity intervention for rectal cancer survivors. structured physical activity interventions will be administered over a three-month period. an exit interview will be conducted at the completion of this time period.

Eligibility criteria:
inclusion criteria: 1. diagnosis of stage i-iii cancers of the rectum/rectosigmoid. 2. age 18 or older 3. three months to 5 years post-treatment completion 4. have a rectal or anal anastomosis with a lars score of 21-42 5. at least 10 participants must be racial/ethnic minority (black/african american, hispanic/latino) 6. ability to be physically active and cleared by md 7. patients must be able to read and understand english. 8. participants must sign the informed consent form the study is open to anyone regardless of gender or ethnicity. efforts will be made to extend the accrual to a representative population, but in a trial which will accrue 20 subjects, a balance must be struck between subject safety considerations and limitations on the number of individuals exposed to potentially toxic or ineffective treatments on the one hand and the need to explore gender, racial, and ethnic aspects of clinical research on the other. if differences in outcome that correlate to gender, racial, or ethnic identity are noted, accrual may be expanded, or additional studies may be performed to investigate those differences more fully. exclusion criteria: 1. patients failing to meet all the above inclusion criteria will be excluded from the study.

Keywords: rectal cancer physical activity bowel dysfunction telehealth
combined er:yag and nd:yag laser protocol for treatment of peri-implantitis

Conditions: Peri-Implantitis

Summary: a laser treatment for periimplantitis using two different wavelengths (er:yag and nd:yag) will be compared to standard treatment in a randomized clinical trial.

the general aim of this study is to evaluate the clinical outcome of the treatment of peri-implantitis using a combination of a er:yag and nd:yag laser protocol or using a conventional mechanical treatment in patients with a diagnosis of peri-implantitis.

Eligibility criteria:
inclusion criteria: * at least one implant with peri-implantitis * no serious mobility of the implants * written informed consent of the voluntary participant in the study * availability of participant for control visits for a follow-up of at least 12 months without interruptions exclusion criteria: * serious systematic disease * pregnancy * current use of photosensitive drugs, bisphosphonate medication or antibiotics * patients who do not want to follow post treatment recommendation of oral hygiene and follow-up visits

Keywords: laser er:yag nd:yag periimplantitis randomized controlled trial
ex-vivo hypotermic perfusion in patients with hepatocellular carcinoma to reduce the incidence of tumor recurrence

Conditions: Liver Carcinoma; Liver Transplant; Tumor Recurrence; Hepato Cellular Carcinoma (HCC); Hypothermic Oxygenated Machine Perfusion

Summary: this is a retrospective study of single-center cohorts that involves patients with hcc who underwent liver transplantation between january 2016 and 2021, who received livers preserved with hypothermic oxygenated perfusion (hope) or static cold storage (scs) with a minum follow up of 12 months.

the gold standard treatment for hepatocellular carcinoma (hcc) is liver transplantation (lt) but, despite its success, it maintains cancer recurrence rates of 16%. ischemia-reperfusion injury (iri) is considered a major determinant of the higher rate of hcc recurrence associated with transplantation from ecd donors and/or organs with ischemic damage. in this field, the treatment with machines perfusion (mp) of the liver has gained increasing attention in the transplant community as a useful tool to relieve iri, test the hepatic function before transplantation and potentially reconditioning the marginal organs. the current study aims to show that hypothermic oxygenated perfusion (hope) can protect recipients not only from iri and post-transplant complications but also from tumour recurrence, which appears to be inevitably linked to the quality of the organ. this will be done through the comparison between a retrospective group of patients with hcc who have undergone lt with graft preserved by hope and a retrospective group of hcc recipients who received grafts preserved without perfusion, but with static cold storage (scs) technique.

Eligibility criteria:
inclusion criteria: * recipients aged 18 years or older with previous diagnosis of hcc, undergone liver transplantation at the transplant center of the irccs aoubo between january 2016 and 2021 * patients who have given informed consent to participate in the study exclusion criteria: * none

Keywords: ex-vivo machine perfusion hepato cellular carcinoma - hcc liver transplantation - lt hcc recurrence after lt hypothermic oxygenated perfusion - hope
the association of hscrp and radiotherapy-induced toxicity in patients with nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma; Head and Neck Cancer; Toxicity Due to Radiotherapy

Summary: the primary purpose of this study is to explore the association of high sensitivity c-reactive protein (hscrp) and radiotherapy(rt)-induced toxicity in patients with nasopharyngeal carcinoma. in each patient, hscrp levels in the pre- and post-rt plasma samples will be measured according to the schedule we set.


Eligibility criteria:
inclusion criteria: * patients were pathologically newly diagnosed with nasopharyngeal carcinoma and had no previous history of other tumors * according to the treatment strategies of doctors, patients need to receive radiotherapy with or without chemotherapy (for example, neoadjuvant chemotherapy, concurrent chemotherapy, adjuvant chemotherapy) or targeted therapy * willingness to sign the informed consent and return to enrolling institution for follow-up and data collection exclusion criteria: * patients do not conform to the inclusion criteria * pregnant or nursing women * men or women of childbearing potential who are unwilling to employ adequate contraception * vital organs dysfunction(for example, kidneys, heart, liver, lungs, brain) * other contraindications or unsuitable conditions for radiotherapy
lopinavir (lpv) dose reduction

Conditions: HIV-1 Infections

Summary: the purpose of this study is to study the pharmacokinetics profiles of generic lopinavir/ritonavir and pediatric aluvia® at reduced dose by assessing safety, tolerability and efficacy.

this is a prospective, 2 arms, randomized intensive pk study with cross over design. this design will provide us optimal information to answer our research question. first and most important, we can assess the pk when lopinavir/r is used in a dose reduced form. by randomizing the patients to either abbott's pediatric aluvia dose reduction or india generic lpv/r dose reduction will allow us to assess the differences in ae severity and frequency. using the standard abbott product as a control our study will provide important information about the bioavailability of the generic product. although it's not an original be design we must be able to make preliminary comparisons.

Eligibility criteria:
inclusion criteria: 1. signed informed consent 2. evidence of hiv infection (confirmed positive elisa and/or documented history of measurable hiv rna) 3. age\> 18 years 4. have been on standard dose of any pi containing regimen for at least 4 weeks prior to study entry 5. currently having no aids defining illness 6. plasma hiv rna \< 50 copies/ml for at least 24 weeks 7. willing to adhere to the protocol requirements exclusion criteria: 1. any history of taking cyp450 inhibitors or inducers, or any gastric acid-reducing drugs within 14 days of enrollment in the study 2. current pregnancy or lactating 3. active opportunistic infection 4. alt/ ast more than 2x upper limit 5. creatinine more than 1.5 time the upper limit 6. relevant history or current condition, illness that might interfere with drug absorption, distribution, metabolism or excretion 7. history of sensitivity/idiosyncrasy to the drug or chemically related compounds or pharmaceutical excipients which may be employed in the study. 8. active drug abuse

Keywords: lopinavir/ritonavir pharmacokinetics hiv-1 infected adults aim to investigate the lower dose of boosted lopinavir in thais and to compare the levels of lopinavir/ritonavir from abbot and gpo
physiological versus right ventricular outcome trial evaluated for bradycardia treatment upgrades

Conditions: Pacing-Induced Cardiomyopathy; Heart Failure

Summary: guidelines for patients having first-time implants advocate that even when heart function is only mildly impaired, modern pacing approaches should be utilised to avoid the potentially damaging effects of rv pacing to preventing symptoms from pacing induced or worsened cardiomyopathy. however, once a traditional (rv) pacemaker is implanted, development of impaired heart function does not prompt a device upgrade. even at the end of battery life, physicians simply replace it like-for-like. this trial tests whether such patients have better symptoms and quality of life if changed to a modern physiological pacing strategy from the traditional rv pacing approach. in this crossover trial, participants will be upgraded to a physiological pacing strategy. after their procedure, they will have a one-month run-in period to recover from the procedure (their pacemaker will be programmed to continued rv pacing). they will be have 2 one-month blinded time periods, randomised to physiological pacing or right ventricular pacing alternately. they will subsequently undergo two six-month blinded randomised time periods. patients will document symptoms monthly on a mobile phone application or computer. at the end of each time period, they will have measurements of heart function, a walking test and quality-of-life questionnaires including the sf-36 questionnaire. the investigators hypothesise that upgrading to physiological pacing strategies will improve patients' quality of life.


Eligibility criteria:
patients with an rv pacemaker and lvef 35-50% and a high burden of right ventricular pacing (\>40%) who are clinically indicated for a cardiac resynchronisation therapy upgrade procedure and: 1. ef reduced by \>5% of increase in lvesv by 10ml since implant 2. nt-probnp \>250ng/l in sinus rhythm 3. nt-probnp \> 750 ng/l if af 4. left atrial volume index \> 30ml/m2 5. regular loop diuretics prescribed 6. decline in daily patient activity by \>1 hour per day since implant 7. decrease in device measured thoracic impedance 8. patient reported decline in functional class or exercise tolerance exclusion criteria: * those unable to provide informed consent * patients under age 18 * pregnant women

Keywords: physiological pacing rv pacing biventricular pacing pacemaker upgrade
avatrombopag for the treatment of thrombocytopenia in adults with chronic liver disease undergoing a procedure

Conditions: Thrombocytopenia

Summary: phase 4 observational cohort study to characterize the treatment patterns and effects of avatrombopag use in patients with thrombocytopenia associated with chronic liver disease who are either undergoing, or have already undergone, a procedure.

data (e.g. type of procedure, platelet count, etc.) will be collected retrospectively or prospectively from patient visits occurring within approximately 7 calendar days prior to the first dose of avatrombopag, on procedure day, on discharge day, and from any clinic visit performed up to 30 days post-procedure. all treatment decisions and clinical assessments will be at the discretion of the treating physician per routine medical care and are not mandated by study design or protocol.

Eligibility criteria:
inclusion criteria: * patient has thrombocytopenia associated with chronic liver disease and is planned for or underwent treatment with avatrombopag prior to a procedure * patient provides written informed consent minimum data for retrospective enrollment * platelet count from approximately 7 days prior to starting avatrombopag * platelet count on procedure day

Keywords: chronic liver disease low platelet count
the effectiveness of hyperbaric oxygen therapy on pneumonia complicating stroke

Conditions: Hyperbaric Oxygen Therapy; Stroke; Pneumonia

Summary: to investigate the evidence for the integration of hyperbaric oxygen therapy (hbot) as part of interdisciplinary stroke rehabilitation.

pneumonia complicating stroke is very difficult to manage and has a very poor prognosis, leading to a significantly higher risk of death. oral opportunistic pathogens have been reported to be associated with the incidence of pneumonia among non-stroke immunocompromised subjects. preliminary studies found that patients with stroke had higher carriage rates of oral opportunistic pathogens than healthy subjects. therefore, investigators hypothesize that pneumonia complicating stroke is associated with oral opportunistic pathogens, and hyperbaric oxygen therapy may reduce the incidence of pneumonia complicating stroke by increasing the flow of saliva, which can affect the species and relative abundance of oral opportunistic pathogens. in order to prove this, investigators need to (1) firstly conduct a randomized controlled trial to confirm whether hyperbaric oxygen therapy is able to reduce the levels of plaque, and the incidence of pneumonia complicating stroke at clinical level; (2) secondly employ metagenomics analysis to compare oral rinse samples and respiratory samples, and to identify pneumonia-associated "oral opportunistic pathogens group"; (3) finally elucidate how hyperbaric oxygen therapy influences the species and relative abundance of oral opportunistic pathogens. this proposed study will provide evidence for the integration of hyperbaric oxygen therapy as part of interdisciplinary stroke rehabilitation.

Eligibility criteria:
inclusion criteria: * new stroke events within 1-3 months (confirmed by ct and mri) * moderate to severe disability (barthel index \< 70) * the patient is conscious, breathing autonomously, not undergoing tracheotomy or tracheal intubation for ventilator-assisted respiration * no concurrent lower respiratory infections and other lung diseases * the condition is relatively stable * cognitive function is normal to moderately impaired (mini-physical state exchange, mmse score\>18) * the gugging swallowing screen (guss) shows swallowing difficulties * no systemic and local use of antibiotic-containing mouthwash exclusion criteria: * a mild disability (barthel index \> 70) * the swallowing function is normal * indwelling nasogastric feeding tube * the neurological status of the patient was significantly dynamically altered (significantly improved or worsened) in the short term prior to inclusion in the trial * the patient had been treated with hyperbaric oxygen for other indications * had a chest condition and cannot withstand the pressure changes caused by hyperbaric oxygen therapy * have an inner ear disease * claustrophobia * communication barriers and inability to give informed consent

Keywords: oral opportunistic pathogens pneumonia complicating stroke metagenome